in vivo News and Research

RSS

S. pneumoniae interacts with other nasopharyngeal bacteria

Streptococcus pneumoniae bacteria are able to detect and respond to other bacterial species in the same host niche, researchers report in Open Biology.

12 May 2014

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Corneal nerve fiber assessment has great potential as a tool to diagnose and monitor peripheral neuropathy induced by HIV, say scientists at the Johns Hopkins University School of Medicine.

12 May 2014

Glutamate imaging reveals ischemic lesions in first 3 hours after stroke, shows research

Glutamate imaging reveals ischemic lesions in the first 3 hours after stroke that are not distinguishable in T1-weighted and T2-weighted imaging.

9 May 2014

ImaginAb announces completion of $21M Series B financing

ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced today the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest.

9 May 2014

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

8 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

New research aids development of better treatments for dry eye

The eye is an exquisitely sensitive system with many aspects that remain somewhat of a mystery-both in the laboratory and in the clinic.

7 May 2014

UNIGE researchers get closer to unraveling mystery of sexual ambiguity

A team of researchers from the University of Geneva (UNIGE) has been involved in a thorough genetic investigation based on the case of a child suffering from the Nivelon-Nivelon-Mabille Syndrome, a complex condition characterised mainly by a sexual development disorder.

6 May 2014

Scientists find key information that may lead to new therapeutic approaches to epilepsy

A team of researchers from Sanford-Burnham Medical Research Institute (Sanford-Burnham) and SUNY Downstate Medical Center (SUNY Downstate) has found that deficiencies in hyaluronan, also known as hyaluronic acid or HA, can lead to spontaneous epileptic seizures.

2 May 2014

Engineering breakthrough allows cancer researchers to create living tumors

Drexel's Wei Sun, PhD, Albert Soffa chair professor in the College of Engineering, has devised a method for 3D printing tumors that could soon be taking cancer research out of the petri dish.

26 Apr 2014

Researchers develop new process to create inexpensive high quality lenses using hanging droplets

A droplet of clear liquid can bend light, acting as a lens. Now, by exploiting this well-known phenomenon, researchers have developed a new process to create inexpensive high quality lenses that will cost less than a penny apiece.

25 Apr 2014

AGA Research Foundation announces 2014 AGA Research Scholars

The American Gastroenterological Association Research Foundation is pleased to announce the 2014 AGA Research Scholars. The AGA Research Scholar Awards program, launched in 1984, enables young investigators to develop independent and productive research careers in digestive diseases. This year, the AGA Research Scholar Awards fund an additional year allowing for three consecutive years of funding.

25 Apr 2014

HemoShear announces research collaboration with Medivir

HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.

23 Apr 2014

Highly advanced imaging method helps to monitor rapid changes in glutathione redox potentials in live cells

In the April issue of Experimental Biology and Medicine a multidisciplinary research team led by Drs. Rex Gaskins and Paul Kenis in the Institute of Genomic Biology (IGB) on the campus of the University of Illinois Urbana-Champaign describe their recent work on subcellular redox homeostasis.

21 Apr 2014

Discovery could have far-reaching implications for diagnosis and treatment of diabetic retinopathy

Indiana University researchers have detected new early-warning signs of the potential loss of sight associated with diabetes. This discovery could have far-reaching implications for the diagnosis and treatment of diabetic retinopathy, potentially impacting the care of over 25 million Americans.

17 Apr 2014

Understanding GPCRs and controlling inflammation: an interview with Dr. Richard Proia, NIDDK, NIH

GPCRs are one of the largest families of cellular signalling proteins consisting of more than a thousand different types. They reside on the surface membranes of cells where they are poised to recognize molecules in the exterior environment and then transmit this information through the membrane allowing cells to respond accordingly.

16 Apr 2014

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.